S-49076

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H22N4O4S
Molecular Weight	438.499
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

SMILES

O=C1CSC(=O)N1CC2=CC3=C(NC(=O)\C3=C/C4=CC(CN5CCOCC5)=CN4)C=C2

InChI

InChIKey=AREYWCZYVPSHGS-NVMNQCDNSA-N

InChI=1S/C22H22N4O4S/c27-20-13-31-22(29)26(20)12-14-1-2-19-17(8-14)18(21(28)24-19)9-16-7-15(10-23-16)11-25-3-5-30-6-4-25/h1-2,7-10,23H,3-6,11-13H2,(H,24,28)/b18-9-

HIDE SMILES / InChI

Approval Year

Targets

Targets

Primary Target	Pharmacology	Potency
Hepatocyte growth factor receptor 54	Inhibitor 8,297	1.0 nM [IC50]
Tyrosine-protein kinase receptor UFO 14	Inhibitor 8,297	7.0 nM [IC50]
Tyrosine-protein kinase Mer 3	Inhibitor 8,297	2.0 nM [IC50]
Fibroblast growth factor receptor 6	Inhibitor 8,297
Tyrosine-protein kinase receptor UFO 14	Inhibitor 8,297	7.0 nM [IC50]
Hepatocyte growth factor receptor 54	Inhibitor 8,297	1.0 nM [IC50]
Fibroblast growth factor receptor 1 45	Antagonist 2,778	18.0 nM [IC50]
Fibroblast growth factor receptor 2 25	Antagonist 2,778	17.0 nM [IC50]
Fibroblast growth factor receptor 3 32	Antagonist 2,778	15.0 nM [IC50]

PubMed

PubMed

Show entries

Title	Date	PubMed
First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours.	2017 Aug	28624695
The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy.	2017 Oct	28619752

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Name

Type

Language

S-49076

Code

English

2,4-THIAZOLIDINEDIONE, 3-((2,3-DIHYDRO-3-((4-(4-MORPHOLINYLMETHYL)-1H-PYRROL-2-YL)METHYLENE)-2-OXO-1H-INDOL-5-YL)METHYL)-

Systematic Name

English

S 49076

Code

English

3-((3-((4-((4-MORPHOLINYL)METHYL)-1H-PYRROL-2-YL)METHYLENE)-2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL)-1,3-THIAZOLIDINE-2,4-DIONE

Systematic Name

English

S-49076(FREE BASE)

Common Name

English

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Code System

Code

Type

Description

MANUFACTURER PRODUCT INFORMATION

S-49076(FREE BASE)

PRIMARY

MedKoo CAT NO: 206484, CAS NO: 1265965-22-7Description: S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream signaling in vitro and in vivo. In cell models, S49076 inhibited the proliferation of MET- and FGFR2-dependent gastric cancer cells, blocked MET-driven migration of lung carcinoma cells, and inhibited colony formation of hepatocarcinoma cells expressing FGFR1/2 and AXL. In tumor xenograft models, a good pharmacokinetic/pharmacodynamic relationship for MET and FGFR2 inhibition following oral administration of S49076 was established and correlated well with impact on tumor growth. MET, AXL, and the FGFRs have all been implicated in resistance to VEGF/VEGFR inhibitors such as bevacizumab. A phase I study with S-49076 is currently underway in patients with advanced solid tumors.

CAS

1265965-22-7

PRIMARY

FDA UNII

65ZUU7MATU

PRIMARY

SMS_ID

300000042471

PRIMARY

PUBCHEM

49870909

PRIMARY